SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc AMGN Amgen NASDAQAMGN

NEW YORK, April 3, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. (“Amgen” or the “Company”) AMGN. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Amgen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On April 27, 2022, Amgen issued an earnings release for its first fiscal quarter of 2022, which disclosed that the Company had received a Notice of Deficiency from the IRS…